Home Tags Kadcyla

Tag: Kadcyla

Ado-trastuzumab Emtansine Fails Phase II/III GATSBY trial

Earlier today, in a short statement to the U.S. Securities Exchange Commission (SEC), ImmunoGen, Inc. disclosed that the Phase II/III Gatsby trial, a clinical...

Initial Results from Phase I Trial with anti-HER2 ADC SYD985 Shows...

Researchers working for Dutch pharmaceutical company Synthon Biopharmaceuticals based in Nijmegen, The Netherlands, report positive initial results from the dose-escalation part of its ongoing first-in-human trial...

Looking Ahead to 2020: Global Antibody-drug Market Prediction

Cytotoxic drugs used in the treatment of solid tumors and hematological malignancies have, over the last 50 years, changed the natural progression of these...

ADAPT Study Shows Promising Results in the Treatment of Patients with...

Results from the German phase II ADAPT study (WSG-ADAPT), showed that neoadjuvant ado-trastuzumab emtansine (T-DM1, Kadcyla®; Genentech/Roche) is effective in the treatment of HER2-positive,...

Takeda and ImmunoGen Sign Licensing Agreement

Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited (Osaka, Japan), and ImmunoGen, Inc. a biotechnology company that develops targeted anticancer therapeutics using its...

ImmunoGen Discontinues IMGN901 Study in Small-Cell Lung Cancer (SCLC)

ImmunoGen has stopped the IMGN901 Phase II SCLC study. The decision is based on the recommendation of the trial's independent Data Monitoring Committee (DMC)....

From the Editors: Welcome to a New Publication – ADC Review/Journal...

Welcome to ADC Review, Journal of Antibody-Drug Conjugates, a new online, peer-reviewed, open-access hybrid publication for those involved in the ongoing--and exciting--development of antibody-drug...